{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "regularMarketChangePercent": -4.5939302, "regularMarketPrice": 34.89, "exchange": "FRA", "shortName": "ARROWHEAD PHARMAC. DL-,01", "longName": "Arrowhead Pharmaceuticals, Inc.", "messageBoardId": "finmb_203142", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "marketState": "REGULAR", "esgPopulated": false, "priceEpsCurrentYear": -43.074074, "sharesOutstanding": 106900000, "bookValue": 4.181, "fiftyDayAverage": 27.6103, "fiftyDayAverageChange": 7.2796993, "fiftyDayAverageChangePercent": 0.26365882, "twoHundredDayAverage": 32.7493, "twoHundredDayAverageChange": 2.1407013, "twoHundredDayAverageChangePercent": 0.06536633, "marketCap": 3821606400, "forwardPE": -72.6875, "priceToBook": 8.3448925, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "2.2 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1106204400000, "priceHint": 2, "regularMarketChange": -1.6800003, "regularMarketTime": 1683898721, "regularMarketDayHigh": 36.47, "regularMarketDayRange": "34.89 - 36.47", "regularMarketDayLow": 34.89, "regularMarketVolume": 20, "regularMarketPreviousClose": 36.57, "bid": 35.39, "ask": 35.69, "bidSize": 1260, "askSize": 1236, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 36.47, "averageDailyVolume3Month": 7, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 13.18, "fiftyTwoWeekLowChangePercent": 0.6070936, "fiftyTwoWeekRange": "21.71 - 47.135", "fiftyTwoWeekHighChange": -12.244999, "fiftyTwoWeekHighChangePercent": -0.2597857, "fiftyTwoWeekLow": 21.71, "fiftyTwoWeekHigh": 47.135, "earningsTimestamp": 1683059400, "earningsTimestampStart": 1690973940, "earningsTimestampEnd": 1691409600, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.31, "epsForward": -0.48, "epsCurrentYear": -0.81, "symbol": "HDP1.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "177 East Colorado Boulevard", "address2": "Suite 700", "city": "Pasadena", "state": "CA", "zip": "91105", "country": "United States", "phone": "626 304 3400", "fax": "626 304 3401", "website": "https://arrowheadpharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.", "fullTimeEmployees": 397, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher R. Anzalone Ph.D.", "age": 53, "title": "CEO, Pres & Director", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 1649420, "fmt": "1.65M", "longFmt": "1,649,420"}, "exercisedValue": {"raw": 996462, "fmt": "996.46k", "longFmt": "996,462"}, "unexercisedValue": {"raw": 14937168, "fmt": "14.94M", "longFmt": "14,937,168"}}, {"maxAge": 1, "name": "Mr. Kenneth A. Myszkowski", "age": 56, "title": "Chief Financial Officer", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": {"raw": 761552, "fmt": "761.55k", "longFmt": "761,552"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Patrick  O'Brien J.D., PharmD", "age": 58, "title": "COO, Gen. Counsel & Sec.", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": {"raw": 749863, "fmt": "749.86k", "longFmt": "749,863"}, "exercisedValue": {"raw": 172200, "fmt": "172.2k", "longFmt": "172,200"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. James C. Hamilton M.D., MBA", "age": 44, "title": "Chief of Discovery & Translational Medicine", "yearBorn": 1978, "fiscalYear": 2022, "totalPay": {"raw": 676814, "fmt": "676.81k", "longFmt": "676,814"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Tracie  Oliver", "title": "Chief Commercial Officer", "fiscalYear": 2022, "totalPay": {"raw": 449579, "fmt": "449.58k", "longFmt": "449,579"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Mark M. Davis Ph.D.", "title": "Founder and Founder & Director of Insert Therapeutics Inc & Calando", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Vincent  Anzalone CFA", "title": "Head of Investor Relations & VP", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Howard  Lovy", "title": "Director of Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Mark  Seefeld", "age": 68, "title": "Head of Toxicology & VP", "yearBorn": 1954, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Javier  San Martin M.D.", "age": 57, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 9, "boardRisk": 8, "compensationRisk": 3, "shareHolderRightsRisk": 1, "overallRisk": 3, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}